NCT05382559 2026-04-14
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
Clinical Trials
68 trialsNCT05919264 2026-04-09
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT03505320 2026-04-03
ILUSTRO
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT06901531 2026-04-03
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT03899155 2026-04-01
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT03203525 2026-02-25
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT03504397 2026-02-13
Spotlight
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT03653507 2026-02-06
GLOW
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT07366528 2026-01-26
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Ruijin Hospital
Phase 3 Recruiting
NCT06385925 2025-12-15
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2 Recruiting
NCT06846346 2025-11-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT02967289 2025-11-17
IROCAS
UNICANCER
Phase 3 Completed
NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT00680901 2025-08-07
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis
Phase 3 Completed
NCT02885753 2025-07-09
OSCAR
Federation Francophone de Cancerologie Digestive
Phase 3 Recruiting
NCT07018063 2025-06-12
YOUNG-NEOS
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT02720068 2025-05-30
MK-4280-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT06028737 2025-05-06
OCTASUR
Ukrainian Society of Clinical Oncology
Phase 2/3 Recruiting
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT02848443 2024-07-25
Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer
Servier
Phase 1 Completed
NCT02842580 2024-07-10
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT00227617 2023-05-22
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Phase 2/3 Terminated
NCT04080843 2022-07-13
ALTER-C-002
Zhejiang University
Phase 2 Completed
NCT02625610 2022-06-09
Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)
EMD Serono
Phase 3 Completed
NCT02178709 2022-04-19
A Phase II Study of Neoadjuvant FOLFIRINOX
Indiana University
Phase 2 Completed
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT01362374 2022-01-12
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01660711 2021-11-08
A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
Endeavor Health
Phase 2 Completed
NCT01858649 2020-10-22
BEV-ONCO2012
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Completed
NCT01633970 2020-10-08
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01522989 2020-03-04
PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies
Georgetown University
Phase 1 Unknown
NCT03961841 2019-12-23
Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Not yet recruiting
NCT04060472 2019-08-19
Paclitaxel (Albumin-bound) and Oxaliplatin for Advanced Hepatobiliary and Malignant Tumors
Third Military Medical University
Phase 2/3 Unknown
NCT01470443 2019-05-21
Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma
Samsung Medical Center
Phase 3 Unknown
NCT00115765 2018-10-17
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
Amgen
Phase 3 Completed
NCT02241551 2018-07-26
Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer
University of Pittsburgh
Phase 2 Terminated
NCT01888978 2018-04-09
Molecularly Tailored Therapy for Pancreas Cancer
Georgetown University
Phase 2 Completed
NCT01308086 2017-08-09
Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer
Hellenic Oncology Research Group
Phase 3 Unknown
NCT01383538 2017-08-08
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
University of California, San Francisco
Phase 1 Completed
NCT00591149 2017-06-14
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
University of Kansas Medical Center
Phase 2 Terminated
NCT00177307 2016-07-12
Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer
University of Pittsburgh
Phase 2 Completed
NCT00659269 2016-02-26
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
New Mexico Cancer Research Alliance
Phase 3 Completed
NCT00557557 2015-12-28
Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases
University of Pittsburgh
Phase 1 Completed
NCT00250835 2015-09-01
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00707278 2014-10-31
Radiation Therapy and Capecitabine/Oxaliplatin Chemotherapy in the Treatment of Locally Advanced Pancreas Adenocarcinoma
University of Utah
Phase 1 Completed